BioNTech

BioNTech SE
	Headquarters in Mainz
Company type	Public
Traded as	Nasdaq: BNTX
ISIN	US09075V1026
Industry	Biotechnology
Founded	2008
Founders	Uğur Şahin; Özlem Türeci; Christoph Huber;
Headquarters	Mainz, Germany
Number of locations	17 (2024)
Area served	Worldwide
Key people	Uğur Şahin (CEO); Annemarie Hanekamp (CCO); Jens Holstein (CFO); Sierk Poetting (COO); Ryan Richardson (CSO); James Ryan (CLO, CBO); Özlem Türeci (CMO);
Products	Pfizer-BioNTech COVID-19 vaccine, Immunotherapy and vaccine candidates
Services	Immunotherapy
Revenue	€2.751 billion (2024)
Operating income	€−1.31 billion (2024)
Net income	€−665 million (2024)
Total assets	€22.53 billion (2024)
Total equity	€19.41 billion (2024)
Number of employees	6,772 (2024)
Website	biontech.com
	Footnotes / references; BioNTech FY 2024 report

BioNTech SE (/biːˈɒntɛk/ bee-ON-tek; or /baɪˈɒntɛk/ bye-ON-tek short for Biopharmaceutical New Technologies) is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.

The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.

In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic.